Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 9/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | CBLB | Q13191 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25891784 | 0.82 | LIPE (0.42) | LIPERIPK1CBLBMAPTSMN1; SMN2 | |
| SCHEMBL25314447 | 0.81 | MAP3K5 (0.47) | LIPEMAPTSMN1; SMN2 | |
| SCHEMBL30389317 | 0.81 | MAP3K5 (0.47) | LIPEMAPTSMN1; SMN2 | |
| SCHEMBL21623038 | 0.79 | LIPE (0.45) | LIPEPDCD1CD274 | |
| SCHEMBL30836779 | 0.78 | LIPE (0.50) | LIPESMN1; SMN2NPC1PDCD1CD274 | |
| SCHEMBL28793298 | 0.78 | LIPE (0.52) | LIPECD274 | |
| SCHEMBL20293126 | 0.76 | LIPE (0.50) | LIPEMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL30836715 | 0.76 | LIPE (0.50) | LIPEMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL31354182 | 0.74 | LIPE (0.37) | LIPESMN1; SMN2TP53 | |
| SCHEMBL31354155 | 0.74 | PDCD1 (0.51) | LIPEPDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | LIPE 2493/4885RIPK1 658/4885CBLB 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.